Drug Profile
Mipicoledine - Dekk Tec
Alternative Names: 4-Demethyl-4-cholesteryloxy-carbonylpenclomedine; DM-CHOC-PEN; Penclomidine derivativeLatest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator Dekk-Tec
- Class Antineoplastics; Carbonates; Chlorinated hydrocarbons; Cyclopentanes; Phenanthrenes; Picolines; Pyridines; Small molecules
- Mechanism of Action Alkylating agents; Cell cycle modulators; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Brain cancer; Brain metastases
- No development reported Solid tumours
Most Recent Events
- 01 Oct 2022 Dekk-Tec completes a phase I trial for Brain cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT03371004)
- 26 Sep 2022 Mipicoledine is still in phase-II clinical trials for Brain metastases (In adolescents, In adults) in USA (IV) (NCT03668847)
- 08 Apr 2022 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)